Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.16
NVAX's Cash to Debt is ranked lower than
78% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. NVAX: 1.16 )
Ranked among companies with meaningful Cash to Debt only.
NVAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 19.44 Max: No Debt
Current: 1.16
Equity to Asset 0.21
NVAX's Equity to Asset is ranked lower than
86% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NVAX: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
NVAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.78 Max: 0.98
Current: 0.21
0.14
0.98
F-Score: 2
Z-Score: -0.18
M-Score: -8.19
WACC vs ROIC
14.04%
-387.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -1381.40
NVAX's Operating margin (%) is ranked lower than
80% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. NVAX: -1381.40 )
Ranked among companies with meaningful Operating margin (%) only.
NVAX' s Operating margin (%) Range Over the Past 10 Years
Min: -11502.46  Med: -824.36 Max: -134.38
Current: -1381.4
-11502.46
-134.38
Net-margin (%) -1405.84
NVAX's Net-margin (%) is ranked lower than
80% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. NVAX: -1405.84 )
Ranked among companies with meaningful Net-margin (%) only.
NVAX' s Net-margin (%) Range Over the Past 10 Years
Min: -12414.15  Med: -880.1 Max: -129.13
Current: -1405.84
-12414.15
-129.13
ROE (%) -99.99
NVAX's ROE (%) is ranked lower than
82% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. NVAX: -99.99 )
Ranked among companies with meaningful ROE (%) only.
NVAX' s ROE (%) Range Over the Past 10 Years
Min: -99.99  Med: -43.4 Max: -32.12
Current: -99.99
-99.99
-32.12
ROA (%) -57.55
NVAX's ROA (%) is ranked lower than
73% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. NVAX: -57.55 )
Ranked among companies with meaningful ROA (%) only.
NVAX' s ROA (%) Range Over the Past 10 Years
Min: -57.55  Med: -33.19 Max: -22.37
Current: -57.55
-57.55
-22.37
ROC (Joel Greenblatt) (%) -799.42
NVAX's ROC (Joel Greenblatt) (%) is ranked lower than
58% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. NVAX: -799.42 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NVAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -799.42  Med: -427.33 Max: -182.47
Current: -799.42
-799.42
-182.47
Revenue Growth (3Y)(%) -6.30
NVAX's Revenue Growth (3Y)(%) is ranked lower than
63% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. NVAX: -6.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NVAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.7  Med: 1.8 Max: 247.6
Current: -6.3
-57.7
247.6
EBITDA Growth (3Y)(%) 41.30
NVAX's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. NVAX: 41.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NVAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.7  Med: -6 Max: 102.6
Current: 41.3
-58.7
102.6
EPS Growth (3Y)(%) 39.70
NVAX's EPS Growth (3Y)(%) is ranked higher than
87% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. NVAX: 39.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NVAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -45.5  Med: -3.3 Max: 52.3
Current: 39.7
-45.5
52.3
» NVAX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NVAX Guru Trades in Q3 2015

Joel Greenblatt 110,640 sh (New)
Jim Simons 1,831,393 sh (+68.70%)
Paul Tudor Jones 34,988 sh (+44.83%)
» More
Q4 2015

NVAX Guru Trades in Q4 2015

Steven Cohen 384,300 sh (New)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q1 2016

NVAX Guru Trades in Q1 2016

George Soros 30,300 sh (New)
Steven Cohen Sold Out
» More
Q2 2016

NVAX Guru Trades in Q2 2016

Steven Cohen 180,000 sh (unchged)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:ARIA, OTCPK:ABCZY, NAS:BLUE, NAS:OPHT, NYSE:PBYI, OTCPK:PTIX, NAS:ITCI, NAS:LGND, NAS:PRTA, OTCPK:AKBLF, NAS:ONCE, NAS:DBVT, NYSE:AXON, NAS:ALDR, NAS:NKTR, OTCPK:GENSF, OTCPK:SXMDF, NAS:LXRX, NAS:AGIO, NAS:RLYP » details
Traded in other countries:NVV.Germany,
Novavax Inc is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.

Novavax Inc was incorporated in 1987 under the laws of the State of Delaware. The Company is a clinical-stage Biopharmaceutical company focused on creating differentiated, value- upon current preventive options for a range of infectious diseases. The Company manages its business as one operating segment: developing recombinant vaccines. The Company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles ('VLPs') and recombinant nanoparticle vaccines combined with a single-use bioprocessing production system. These vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate immunologically important recombinant proteins. Its influenza VLPs contain three of the structural virus proteins that are important for fighting influenza: hemagglutinin (HA) and neuraminidase (NA), both of which stimulate the body to produce antibodies that neutralize the influenza virus and prevent its spread through the cells in the respiratory tract, and matrix 1 (M1), which stimulates cytotoxic T lymphocytes to kill cells that may already be infected. The Company's product pipeline targets a variety of infectious diseases and its vaccine candidates are currently in or have completed clinical trials that target pandemic influenza (H5N1), seasonal influenza and respiratory syncytial virus ('RSV'). The Company's main competitors includes sanofi pasteur, Inc, MedImmune, LLC (a subsidiary of AstraZeneca PLC), GlaxoSmithKline plc, Novartis, Inc., and Merck & Co., Inc., Protein Sciences Corporation. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential federal, state or local regulations.

Ratios

vs
industry
vs
history
P/B 17.70
NVAX's P/B is ranked lower than
90% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. NVAX: 17.70 )
Ranked among companies with meaningful P/B only.
NVAX' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 3.84 Max: 18.77
Current: 17.7
1.02
18.77
P/S 101.54
NVAX's P/S is ranked lower than
86% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. NVAX: 101.54 )
Ranked among companies with meaningful P/S only.
NVAX' s P/S Range Over the Past 10 Years
Min: 6.47  Med: 59.07 Max: 1903.33
Current: 101.54
6.47
1903.33
Current Ratio 5.13
NVAX's Current Ratio is ranked higher than
54% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. NVAX: 5.13 )
Ranked among companies with meaningful Current Ratio only.
NVAX' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.42 Max: 37
Current: 5.13
0.44
37
Quick Ratio 5.13
NVAX's Quick Ratio is ranked higher than
56% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. NVAX: 5.13 )
Ranked among companies with meaningful Quick Ratio only.
NVAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 4.37 Max: 37
Current: 5.13
0.44
37
Days Sales Outstanding 6.94
NVAX's Days Sales Outstanding is ranked higher than
90% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. NVAX: 6.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 6.94  Med: 73.44 Max: 289.75
Current: 6.94
6.94
289.75

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 7.00
NVAX's Yield on cost (5-Year) is ranked higher than
91% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. NVAX: 7.00 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
NVAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 7
3-Year Average Share Buyback Ratio -22.20
NVAX's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. NVAX: -22.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -29.9  Med: -19.3 Max: -8.1
Current: -22.2
-29.9
-8.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 360.50
NVAX's Price/Net Current Asset Value is ranked lower than
100% of the 618 Companies
in the Global Biotechnology industry.

( Industry Median: 5.45 vs. NVAX: 360.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NVAX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.75  Med: 11.65 Max: 419
Current: 360.5
3.75
419
Price/Tangible Book 42.41
NVAX's Price/Tangible Book is ranked lower than
95% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. NVAX: 42.41 )
Ranked among companies with meaningful Price/Tangible Book only.
NVAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.02  Med: 8.69 Max: 170.61
Current: 42.41
3.02
170.61
Price/Median PS Value 1.72
NVAX's Price/Median PS Value is ranked lower than
78% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. NVAX: 1.72 )
Ranked among companies with meaningful Price/Median PS Value only.
NVAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.97 Max: 22
Current: 1.72
0.07
22
Earnings Yield (Greenblatt) (%) -13.74
NVAX's Earnings Yield (Greenblatt) (%) is ranked lower than
60% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. NVAX: -13.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NVAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -169.5  Med: 0 Max: 0
Current: -13.74
-169.5
0

More Statistics

Revenue (TTM) (Mil) $19.10
EPS (TTM) $ -1.00
Beta1.66
Short Percentage of Float28.53%
52-Week Range $4.08 - 11.73
Shares Outstanding (Mil)271.19

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 20 49 50
EPS ($) -1.11 -0.99 -1.20
EPS w/o NRI ($) -1.11 -0.99 -1.20
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: United States Steel Corp, Tuesday Morning Corp, Novavax Inc. Feb 08 2015 
Novavax Inc. Reports Operating Results (10-Q) Nov 08 2010 
Novavax Inc. Reports Operating Results (10-Q) Aug 06 2010 
Novavax Inc. Reports Operating Results (10-Q) May 10 2010 
Novavax Inc. Reports Operating Results (10-Q) Nov 09 2009 
Novavax Inc. Reports Operating Results (10-Q) Aug 10 2009 
Novavax Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
This Small-Cap Vaccine Company Offers 14.5% Upisde, Vetr Crowd Says Aug 24 2016
Novavax, Inc. breached its 50 day moving average in a Bullish Manner : NVAX-US : August 24, 2016 Aug 24 2016
ETF’s with exposure to Novavax, Inc. : August 23, 2016 Aug 23 2016
NOVAVAX INC Financials Aug 18 2016
ETF’s with exposure to Novavax, Inc. : August 12, 2016 Aug 12 2016
Novavax, Inc. :NVAX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
Novavax, Inc. breached its 50 day moving average in a Bearish Manner : NVAX-US : August 11, 2016 Aug 11 2016
[$$] Novavax Vaccine May Be Game Changer Aug 11 2016
NOVAVAX INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 11 2016
Edited Transcript of NVAX earnings conference call or presentation 9-Aug-16 8:30pm GMT Aug 10 2016
Novavax (NVAX) Stock Dropping as Q2 Results Miss Expectations Aug 10 2016
How Will Novavax (NVAX) Stock React After Q2 Miss? Aug 09 2016
Novavax reports 2Q loss Aug 09 2016
Novavax reports 2Q loss Aug 09 2016
Novavax Reports Second Quarter 2016 Financial Results - Aug 09 2016
NOVAVAX INC Files SEC form 10-Q, Quarterly Report Aug 09 2016
Novavax Reports Second Quarter 2016 Financial Results Aug 09 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)